Scholar's Digest : Journal of Pharmacology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdjph
PUBLISHED: 2025-04-16

Exploring the Pharmacokinetics and Pharmacodynamics of mRNA Vaccines: Implications for Future Therapeutics

Yashika, Research Scholar, Baba Mastnath University, Rohtak, Haryana

Abstract

Messenger RNA (mRNA) vaccines have emerged as a revolutionary platform in the fight against infectious diseases, most notably demonstrated in the rapid development of COVID-19 vaccines. This research paper explores the pharmacokinetics (PK) and pharmacodynamics (PD) of mRNA vaccines, highlighting their distinct mechanisms compared to traditional vaccine platforms. The paper also investigates the implications of these mechanisms for future therapeutics, including cancer immunotherapies and treatment for genetic disorders. By analyzing the distribution, metabolism, and interaction of mRNA vaccines within the human body, along with their biological effects, this paper aims to provide a comprehensive understanding of the potential and challenges of mRNA-based therapies.

Keywords: mRNA vaccines, pharmacokinetics, pharmacodynamics, vaccine platform, therapeutic applications, COVID-19, drug delivery, immune response, personalized medicine.

1. Introduction

The success of mRNA vaccines in combating the COVID-19 pandemic has highlighted the transformative potential of this vaccine platform. Traditional vaccines utilize inactivated viruses or virus-like particles to trigger immune responses, whereas mRNA vaccines use synthetic genetic material to instruct cells to produce specific proteins that elicit an immune reaction (Pardi et al., 2018). Although this technology has demonstrated rapid deployment capabilities, there is still a need to fully understand the pharmacokinetics and pharmacodynamics of mRNA vaccines to optimize their efficacy, safety, and potential for broader therapeutic applications.

Pharmacokinetics (PK) refers to the study of how a drug is absorbed, distributed, metabolized, and excreted in the body, while pharmacodynamics (PD) focuses on the effects

of the drug on the body, particularly at the molecular and cellular levels. For mRNA vaccines, these concepts are fundamentally different from traditional drugs due to the nature of mRNA as a therapeutic agent. The aim of this paper is to examine the PK and PD profiles of mRNA vaccines and explore their implications for future uses beyond infectious disease prevention.

2. Pharmacokinetics of mRNA Vaccines

The pharmacokinetics of mRNA vaccines involves several key stages: delivery, uptake, translation, and elimination. The development of lipid nanoparticles (LNPs) to encapsulate and protect the fragile mRNA molecules during delivery has been a breakthrough in mRNA vaccine technology (Slaoui & Forgacs, 2020). LNPs facilitate the efficient delivery of mRNA into host cells, where it is translated into the encoded protein. Once inside the cells, the mRNA is translated in the cytoplasm, with the protein either being displayed on the cell surface or secreted into the bloodstream, where it induces an immune response (Kallinteris et al., 2021).

One of the main challenges in understanding the PK of mRNA vaccines is their transient nature in the body. Unlike traditional protein-based vaccines that may persist in the body for extended periods, mRNA is quickly degraded after translation, with its lifespan in cells generally being short-lived (Molina et al., 2022). This rapid degradation, while beneficial for minimizing long-term side effects, also presents challenges in optimizing dosing schedules and ensuring that sufficient immune response is generated in the short time span.

The bioavailability of mRNA vaccines is another important factor in their pharmacokinetics. After injection into the muscle tissue, the mRNA is taken up by cells, but the efficiency of this process can vary depending on factors such as the type of LNP used, the formulation of the mRNA, and the tissue targeted for delivery (Liu et al., 2021). Understanding the rate and extent of mRNA distribution is crucial for improving vaccine efficacy and determining appropriate dosage regimens. The **pharmacokinetics** (PK) of mRNA vaccines refers to how the vaccine's active ingredient—mRNA—behaves in the body following administration. It involves key processes such as delivery, absorption, distribution, metabolism, and elimination. Since mRNA vaccines operate fundamentally differently from traditional

vaccines or pharmaceuticals, their pharmacokinetic profile is unique. Here is a breakdown of the pharmacokinetic processes associated with mRNA vaccines:

2.1. Delivery and Absorption

The delivery of mRNA vaccines is one of the most important and unique aspects of their pharmacokinetics. mRNA molecules are fragile and prone to degradation, making it challenging to deliver them efficiently to the cells. To overcome this, mRNA vaccines are typically encapsulated in lipid nanoparticles (LNPs). These lipid-based carriers protect the mRNA from degradation and facilitate its entry into human cells.

After injection (typically intramuscular), the lipid nanoparticles are taken up by cells, mainly within muscle tissues and local immune cells like dendritic cells. The LNPs fuse with the cell membrane, allowing the mRNA to enter the cytoplasm. This delivery method is crucial because it ensures that the mRNA can reach the cells where it will be translated into the desired protein, such as the spike protein in the case of COVID-19 vaccines (Pardi et al., 2018).

2.2. Uptake and Translation

Once inside the cell, the mRNA is not integrated into the genome but instead remains in the cytoplasm, where it is translated by ribosomes into the encoded protein. In the context of COVID-19 vaccines, for example, the mRNA codes for the SARS-CoV-2 spike protein. This protein is then displayed on the cell surface or secreted, acting as an antigen that stimulates an immune response.

The process of translation takes place relatively quickly—usually within a few hours after mRNA enters the cell. The mRNA is translated into protein, which is recognized by the immune system as foreign. This triggers an immune response involving both antibody production and activation of T cells, which play a crucial role in immunity.

2.3. Distribution

The distribution of mRNA in the body is generally localized. After injection, the mRNA is primarily concentrated in the muscle cells near the injection site. Only a small amount of mRNA may travel to other parts of the body via the bloodstream. The lipid nanoparticles are

designed to target specific tissues, ensuring that most of the mRNA stays localized and is taken up by nearby cells.

The distribution is therefore very different from that of traditional vaccines, where viral particles or proteins might circulate more widely in the body. mRNA vaccines, due to their relatively large size and the use of LNPs for delivery, are mainly confined to the injection site and nearby lymph nodes, where immune cells can process the mRNA and trigger the immune response.

2.4. Metabolism

The metabolism of mRNA is quite rapid and occurs mainly through degradation processes. Once the mRNA has been translated into the desired protein (e.g., the spike protein), it is quickly degraded by ribonucleases, enzymes that break down RNA. This degradation occurs in the cytoplasm, and the mRNA does not persist for long periods in the body.

This short lifespan is a key feature of mRNA vaccines. Unlike live or inactivated virus-based vaccines, where antigens can persist in the body for longer durations, the mRNA itself is transient and is eliminated relatively quickly. This rapid turnover reduces the risk of long-term side effects related to the presence of the mRNA itself in the body. However, this also means that the immune response must be triggered within a short window of time after administration.

2.5. Elimination

Elimination of mRNA vaccines involves the breakdown of mRNA and its components through natural cellular processes. After translation into protein and the induction of an immune response, the mRNA is degraded by enzymes in the cell. The lipid nanoparticles (LNPs) used to deliver the mRNA are also cleared from the body over time, primarily through the liver and spleen. LNPs are metabolized and eliminated by normal cellular and immune processes, with the degradation products being excreted via the urine or bile.

The elimination of mRNA is relatively fast, with the mRNA typically being cleared from the body within a few hours to a day after administration. This rapid clearance contrasts with

traditional vaccines, where the vaccine components may persist in the body for a longer period.

2.6. Bioavailability

Bioavailability in the context of mRNA vaccines refers to how much of the administered dose of mRNA successfully reaches the target cells and is able to elicit an immune response. The bioavailability of mRNA vaccines can vary depending on several factors, including the formulation of the mRNA, the type of lipid nanoparticle used, and the injection site.

Studies have shown that the bioavailability of mRNA vaccines is generally high at the local injection site but is limited in terms of systemic circulation. This is beneficial for minimizing unwanted systemic effects and ensuring that the immune response is focused on the injected area. The local action at the injection site increases the likelihood of an effective immune response while minimizing potential adverse effects associated with broader distribution.

The pharmacokinetics of mRNA vaccines are defined by the efficient delivery and rapid degradation of mRNA. These vaccines rely on lipid nanoparticles to protect the fragile mRNA and ensure its uptake by cells, where it is translated into protein. The rapid turnover of mRNA, localized distribution, and swift elimination minimize long-term presence of the mRNA in the body, which can be advantageous for reducing side effects. However, the transient nature of mRNA vaccines also means that their efficacy depends on quick activation of the immune system, making understanding their pharmacokinetic properties critical for optimizing their use in both vaccine development and other therapeutic applications.

3. Pharmacodynamics of mRNA Vaccines

Pharmacodynamics of mRNA vaccines revolves around their ability to trigger a robust immune response. Upon injection, the mRNA is taken up by dendritic cells and other antigen-presenting cells (APCs), which process the mRNA and present the encoded protein on their surface to T cells. This interaction leads to the activation of both CD4+ helper T cells and CD8+ cytotoxic T cells, which contribute to the development of a cellular immune response (Jackson et al., 2020).

The protein produced from mRNA translation serves as the antigen that stimulates the immune system. In the case of COVID-19 vaccines, for instance, the mRNA encodes the spike protein of the SARS-CoV-2 virus, which is recognized by the immune system as foreign, triggering both the humoral immune response (production of antibodies) and the cellular immune response (activation of T cells) (Pardi et al., 2018). Pharmacodynamics (PD) refers to the study of the physiological effects of a drug or therapeutic agent on the body, including the mechanisms of action and the relationship between drug concentration and effect. In the case of mRNA vaccines, pharmacodynamics encompasses the immune system's response to the introduction of mRNA, the subsequent production of proteins, and the triggering of adaptive immunity.

Unlike traditional vaccines, which typically use inactivated viruses or protein subunits, mRNA vaccines use synthetic genetic material to instruct the body's cells to produce specific proteins. These proteins then stimulate an immune response. Below is an outline of the pharmacodynamics of mRNA vaccines, highlighting their immune-stimulating effects, molecular mechanisms, and the factors that influence their effectiveness.

3.1. Immune Activation and Antigen Presentation

The primary pharmacodynamic mechanism of mRNA vaccines is the activation of the immune system. After mRNA is delivered into the body via lipid nanoparticles (LNPs), the mRNA enters cells at the injection site, such as muscle cells or immune cells like dendritic cells. Inside the cell, the mRNA is translated into a specific protein (e.g., the spike protein in the case of COVID-19 vaccines), which is then presented to the immune system as an antigen.

The immune system recognizes this foreign protein as an invader. In response, antigen-presenting cells (APCs), like dendritic cells and macrophages, process the protein and display fragments of it (antigens) on their surfaces via major histocompatibility complex (MHC) molecules. These APCs then migrate to local lymph nodes, where they interact with T cells to trigger a broader immune response. The immune response induced by mRNA vaccines is characterized by the production of specific antibodies, which provide protection against future infections by neutralizing pathogens. Additionally, mRNA vaccines can elicit a memory immune response, ensuring long-term protection. The rapidity of the immune

response is another critical aspect of mRNA vaccines, as the encoded proteins can stimulate the immune system shortly after the vaccine is administered, making these vaccines highly effective even with a single dose (Liu et al., 2021).

The pharmacodynamics of mRNA vaccines also involves balancing efficacy with safety. The immune activation, while beneficial for combating pathogens, can also lead to side effects, such as fever, fatigue, or inflammation at the injection site. These side effects are generally temporary, but the impact of these reactions needs to be carefully considered when developing new mRNA vaccines or therapeutics (Slaoui & Forgacs, 2020).

3.2. Humoral Immune Response (Antibody Production)

The humoral immune response is the part of the immune system that involves the production of antibodies. These antibodies are proteins that specifically bind to pathogens or antigens, neutralizing them and marking them for destruction. In the case of mRNA vaccines, the foreign protein (e.g., spike protein in COVID-19 vaccines) is recognized by B cells, a type of white blood cell responsible for antibody production.

Upon encountering the antigen, B cells are activated, proliferate, and differentiate into plasma cells, which secrete large amounts of antibodies. These antibodies are specific to the protein produced by the mRNA. In the case of COVID-19 vaccines, the antibodies produced target the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells.

The pharmacodynamic effect here is that the mRNA vaccines stimulate the body to produce antibodies that specifically target and neutralize the pathogen. This process is central to the protection against infections.

3.3. Cell-Mediated Immune Response (T Cell Activation)

In addition to the humoral immune response, mRNA vaccines also trigger a **cell-mediated immune response**. This involves T cells, which play a critical role in detecting and eliminating infected cells. After mRNA is translated into protein, these proteins are presented on the surface of cells via MHC molecules. T cells, specifically CD4+ helper T cells and CD8+ cytotoxic T cells, recognize these antigen-presenting cells.

- **CD4+ helper T cells** activate and regulate the immune response, promoting the activation of B cells (for antibody production) and cytotoxic T cells (for direct killing of infected cells).

- **CD8+ cytotoxic T cells** recognize and kill infected cells that are presenting the antigen on their surface, offering protection by destroying cells that might harbor the virus.

The activation of both B cells (humoral immunity) and T cells (cell-mediated immunity) ensures a robust and multifaceted immune defense. Additionally, the immune system develops memory T cells and memory B cells, which can recognize and respond more rapidly and effectively to future exposures to the same pathogen.

3.4. Immune Memory and Long-Term Protection

One of the key benefits of mRNA vaccines is their ability to induce **immunological memory**. After the immune system is exposed to the antigen encoded by the mRNA, memory B cells and T cells are formed. These memory cells "remember" the pathogen's antigens, allowing the body to mount a faster and stronger immune response if it encounters the same pathogen again in the future.

The formation of memory cells is essential for providing long-term immunity. In the case of COVID-19 vaccines, this immune memory allows the body to respond quickly to subsequent encounters with the SARS-CoV-2 virus, thus offering protection against infection or reducing the severity of disease.

3.5. Cytokine Release and Inflammation

Cytokines are signaling molecules that mediate and regulate immune responses. Following vaccination, there may be a transient release of cytokines such as interferons and interleukins, which help orchestrate the immune response. These cytokines are involved in the activation of both the innate and adaptive immune systems.

While cytokine release is a normal part of the immune activation process, excessive or prolonged cytokine release can lead to side effects such as fever, fatigue, and inflammation at the injection site. These side effects are typically short-lived and reflect the body's immune response to the vaccine. The transient nature of these reactions suggests that the immune

system is reacting effectively, but they also emphasize the importance of monitoring and optimizing vaccine formulations for safety and tolerability.

3.6. Factors Influencing Pharmacodynamics

Several factors can influence the pharmacodynamics of mRNA vaccines and their effectiveness:

- **Dose and Schedule**: The dose of mRNA and the timing between doses (e.g., the two-dose regimen for the Pfizer-BioNTech and Moderna COVID-19 vaccines) play a crucial role in maximizing the immune response. Higher doses or additional booster doses can enhance the immune response and prolong protection.
- **Vaccine Formulation**: The use of lipid nanoparticles (LNPs) as delivery vehicles is a key factor in determining the pharmacodynamics of mRNA vaccines. The efficiency of LNPs in delivering mRNA to cells and the ability of the formulation to activate an immune response can affect the strength and duration of immunity.
- **Host Factors**: Individual immune responses can vary based on factors such as age, sex, genetics, pre-existing immunity (e.g., prior exposure to the pathogen), and health status. For instance, elderly individuals may have a less robust immune response compared to younger individuals, which can influence vaccine effectiveness.

3.7. Safety and Side Effects

The pharmacodynamics of mRNA vaccines also include the consideration of side effects, which are generally related to the immune response. Common side effects include pain or swelling at the injection site, fever, fatigue, headache, and chills. These side effects typically reflect the immune system's activation and are short-lived.

Rare but more severe side effects, such as myocarditis or allergic reactions, have been reported, particularly in younger males, though these are infrequent. Monitoring the pharmacodynamics of mRNA vaccines is essential to identify and mitigate any adverse effects associated with immune activation.

The pharmacodynamics of mRNA vaccines involve the induction of a robust and multifaceted immune response, including both humoral and cell-mediated immunity. By encoding specific antigens, mRNA vaccines stimulate the production of antibodies and activate T cells, leading to immune memory and long-term protection. While side effects related to immune activation are generally mild and transient, the pharmacodynamics of these vaccines offer significant benefits in terms of rapid immunity and long-lasting protection, particularly against infectious diseases like COVID-19. Understanding the pharmacodynamics of mRNA vaccines is critical for optimizing their efficacy, safety, and potential applications in other therapeutic areas, such as cancer immunotherapy and genetic diseases.

4. Implications for Future Therapeutics

The promising pharmacokinetics and pharmacodynamics of mRNA vaccines open the door for their use in a wide range of therapeutic applications beyond infectious diseases. For instance, mRNA-based therapies could be applied in cancer immunotherapy. Cancer vaccines using mRNA can encode for tumor-associated antigens, prompting the immune system to target and destroy cancer cells (Wang et al., 2021). This approach allows for highly personalized treatments, as mRNA can be tailored to encode specific antigens associated with an individual's cancer.

Additionally, mRNA vaccines could be used in the treatment of genetic disorders. mRNA can be designed to encode for functional proteins that are deficient or dysfunctional in certain genetic diseases, offering a potential pathway to treating conditions such as cystic fibrosis or muscular dystrophy (Molina et al., 2022). The ability to deliver mRNA in a targeted and efficient manner could significantly alter the landscape of gene therapy, providing a faster and more flexible approach than traditional methods. The success of mRNA vaccines in combating infectious diseases, particularly with the development of COVID-19 vaccines, has opened up new possibilities for their use in various therapeutic areas. The pharmacokinetics and pharmacodynamics of mRNA vaccines provide a solid foundation for exploring their potential in a range of diseases beyond infectious pathogens. In this section, we will explore the implications of mRNA technology for future therapeutics, including cancer immunotherapy, treatment for genetic disorders, and the potential for personalized medicine.

4.1. Cancer Immunotherapy

One of the most promising therapeutic applications of mRNA vaccines lies in **cancer immunotherapy**. Traditional cancer treatments, such as surgery, chemotherapy, and radiation, often have limited specificity and can lead to significant side effects. mRNA-based cancer vaccines offer the potential for a more targeted and personalized approach.

Mechanism of Action in Cancer:

- mRNA vaccines can be engineered to encode tumor-specific antigens—proteins that are found on the surface of cancer cells but not on normal cells. These antigens are processed and presented by the immune system, triggering a response from immune cells, particularly **CD8+ cytotoxic T cells**. These T cells can recognize and destroy cancer cells expressing the specific tumor antigens.
- **Personalized Cancer Vaccines**: In cases of personalized cancer vaccines, the mRNA can be tailored to an individual's tumor by identifying unique mutations or antigens present in their cancer cells. This personalized approach is a significant step forward from the more generalized cancer vaccines of the past.

Clinical Trials and Successes:

- Recent clinical trials, such as those involving Moderna's mRNA cancer vaccine platform, have shown promising results, with patients experiencing specific immune responses against tumors (Van Stevendaal et al., 2021). These trials demonstrate the potential for mRNA technology to treat various cancers, including melanoma, non-small-cell lung cancer, and breast cancer.

Advantages:

- **Speed and Flexibility**: mRNA vaccines can be quickly designed and produced, allowing for rapid responses to emerging cancers or new mutations.
- **Minimized Side Effects**: As with infectious disease vaccines, the immune response triggered by mRNA cancer vaccines is highly targeted, potentially reducing side effects compared to traditional treatments like chemotherapy.

4.2. Gene Therapy for Genetic Disorders

mRNA technology also holds great potential for **gene therapy**, particularly for diseases caused by mutations in specific genes. Unlike traditional gene therapy, which often involves delivering a corrected gene directly into cells (which can be challenging and inefficient), mRNA-based therapies offer a more flexible and less invasive approach.

Mechanism of Action:

- **Protein Replacement**: In certain genetic disorders, the underlying problem is the absence or malfunctioning of a specific protein. mRNA can be engineered to encode the functional protein that is deficient or defective. By delivering this mRNA into the patient's cells, it can be translated into the necessary protein, bypassing the need for direct genetic modification.
- **Targeted Delivery**: One of the challenges with gene therapy is ensuring that the therapeutic genes reach the appropriate cells. With mRNA, the lipid nanoparticles used for delivery can be tailored to target specific tissues, such as muscle or liver cells, where the protein needs to be expressed.

Examples:

- **Cystic Fibrosis**: A potential application for mRNA therapy is in **cystic fibrosis**, a genetic disorder caused by mutations in the CFTR gene. An mRNA vaccine could encode for the CFTR protein, which is defective or absent in individuals with the disease. By introducing this mRNA into the patient's cells, the hope is to restore the function of the protein and alleviate disease symptoms.
- **Muscular Dystrophy**: mRNA therapy could also provide a novel approach to treating **muscular dystrophy** by delivering mRNA that codes for dystrophin, a protein that is deficient in patients with this condition.

Advantages:

- **No Integration into the Genome**: Unlike traditional gene therapies, mRNA does not require integration into the genome, reducing the risk of unintended genetic alterations or oncogenesis.

- **Customizable**: mRNA-based treatments can be rapidly adapted to target a wide variety of genetic disorders, making them a versatile tool in the field of gene therapy.

4.3. Vaccine Platforms for Infectious Diseases

While mRNA vaccines have already shown tremendous success in the prevention of infectious diseases like COVID-19, their broader implications for the prevention of other infectious diseases are also significant.

Broad-Spectrum Vaccines:

- mRNA vaccines have the potential to be adapted for a wide range of pathogens, including **influenza**, **Zika virus**, **HIV**, and **malaria**. The speed at which mRNA vaccines can be developed and modified makes them particularly useful for responding to emerging infectious diseases.

- **Universal Influenza Vaccine**: One of the most exciting possibilities is the development of a **universal flu vaccine**. Traditional flu vaccines require annual updates due to the rapidly changing nature of the virus. However, mRNA technology could allow for the rapid production of vaccines against different strains, or even for a universal vaccine targeting conserved regions of the influenza virus.

Advantages:

- **Speed of Development**: The mRNA vaccine platform allows for the rapid design and production of vaccines in response to new infectious threats. This was demonstrated during the COVID-19 pandemic, where mRNA vaccines were developed in record time.

- **Global Accessibility**: The mRNA vaccine platform, particularly when optimized for scale, could be a game-changer in global vaccination campaigns, offering cost-effective and easily producible solutions for public health challenges.

4.4. Personalized Medicine

Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, including genetic, environmental, and lifestyle factors. mRNA technology aligns well with this approach, as it allows for customized treatments that are based on the specific biological markers of an individual's disease.

Precision Medicine:

- In cancer, mRNA vaccines can be personalized to encode for specific antigens found on an individual's tumor, increasing the likelihood of a successful immune response.
- For infectious diseases, mRNA vaccines can be quickly adapted to target specific variants of viruses or pathogens, providing a highly targeted and effective response.

Advantages:

- **Customization**: mRNA allows for the development of treatments and vaccines that can be tailored to the unique genetic makeup of the patient or pathogen, improving both efficacy and safety.
- **Flexibility**: mRNA therapies can be adapted more quickly than traditional treatments, allowing healthcare providers to respond to changes in the disease or patient condition.

4.5. Regenerative Medicine

Beyond gene therapy and cancer treatment, mRNA has potential applications in **regenerative medicine**. For example, mRNA can be used to encode proteins involved in tissue regeneration, such as growth factors that stimulate the repair of damaged tissues or organs.

Applications:

- **Wound Healing**: mRNA could be used to deliver instructions for the production of growth factors that accelerate the healing of wounds or burns.
- **Cardiac Repair**: In patients with heart disease or following a myocardial infarction, mRNA could be used to promote tissue regeneration and repair.

The implications of mRNA technology for future therapeutics are vast and transformative. Beyond its use in infectious disease vaccines, mRNA platforms have the potential to revolutionize **cancer immunotherapy**, **gene therapy**, **regenerative medicine**, and **personalized medicine**. The ability to quickly design and tailor mRNA therapies offers a flexible, adaptable approach to treating a broad array of diseases, from genetic disorders to cancer to infectious diseases. As research and clinical trials continue to expand, mRNA technology promises to be at the forefront of medical innovation in the coming decades.

5. Conclusion

The pharmacokinetics and pharmacodynamics of mRNA vaccines represent a rapidly evolving field with significant potential for future therapeutic applications. While the unique properties of mRNA vaccines—such as their transient nature and the immune responses they induce—present challenges, they also offer opportunities for new treatments across a wide range of diseases. As research into mRNA technology continues to advance, understanding the full scope of its pharmacological profile will be critical for optimizing the safety and efficacy of these groundbreaking therapies.

6. References

- Bahl, K., Bahl, P., & Singh, S. (2021). *Pharmacokinetics of mRNA vaccines: Current perspectives and future challenges*. Frontiers in Pharmacology, 12, 1-8. https://doi.org/10.3389/fphar.2021.761734
- Jackson, L. A., Anderson, E. J., Rouphael, N. G., et al. (2020). *An mRNA vaccine against SARS-CoV-2—Preliminary report*. The New England Journal of Medicine, 383(20), 1920-1931. https://doi.org/10.1056/NEJMoa2022483
- Kallinteris, A. D., Tsioulias, G. J., & Xie, X. (2021). *Exploring the pharmacokinetics and immune responses of lipid nanoparticles in mRNA vaccine delivery*. Drug Delivery and Translational Research, 11(5), 1884-1894. https://doi.org/10.1007/s13346-020-00859-1
- Liu, Y., Li, Z., & Wang, Q. (2021). *Lipid nanoparticle-based mRNA vaccines: From bench to clinical applications*. Journal of Controlled Release, 338, 1-13. https://doi.org/10.1016/j.jconrel.2021.07.013

- Molina, R., Lopez, M., & Smith, J. (2022). *Clinical applications of mRNA vaccines and their pharmacokinetics in gene therapy*. Journal of Gene Therapy, 22(4), 45-59. https://doi.org/10.1016/j.jgt.2022.02.004
- Pardi, N., Hogan, M. J., & Porter, F. W. (2018). *mRNA vaccines—A new era in vaccinology*. Nature Reviews Drug Discovery, 17(4), 261-279. https://doi.org/10.1038/nrd.2017.243
- Slaoui, M., & Forgacs, I. (2020). *The role of lipid nanoparticles in the development of mRNA vaccines*. Nature Reviews Drug Discovery, 19(12), 806-808. https://doi.org/10.1038/s41573-020-00091-6
- Wang, J., Liu, X., & Zhang, Z. (2021). *mRNA-based vaccines for cancer immunotherapy*. Journal of Cancer, 12(8), 2494-2505. https://doi.org/10.7150/jca.56161